Pipeline

Innovation is in GenSci's DNA. GenSci advances a robust, innovative portfolio across four therapeutic areas: endocrinology & metabolism, women's health, immunology & respiratory diseases, and oncology.

The pipeline is updated quarterly. Last updated December 2025.
The pipeline is approved in at least one major market, such as China, USA and/or EU.
Only selected pipeline molecules are presented here.

Women's Health Pipeline

Molecule

Indication(s)

Target(s)

IND

Phase Ⅰ

Phase Ⅱ

Phase Ⅲ

Registration

Launch

Human Follitropin Injection

COH, OI
(Induction of Ovulation)

FSHR

Progesterone Injection (II)

Luteal Support in ART

PR

GenSci074

VMS

NK3R

GenSci142

BV (Gardnerella)

Peptidoglycan

Women's Health Pipeline

- IND
- Phase Ⅰ
- Phase Ⅱ
- Phase Ⅲ
- Registration
- Launch
- Human Follitropin Injection
  
  COH, OI
  (Induction of Ovulation)
  
  FSHR
- Progesterone Injection (II)
  
  Luteal Support in ART
  
  PR
- GenSci074
  
  VMS
  
  NK3R
- GenSci142
  
  BV (Gardnerella)
  
  Peptidoglycan